Literature DB >> 22252547

Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care.

Massimo Destro1, Luca Ottolini, Lorenza Vicentini, Silvia Boschetti.   

Abstract

The parenteral administration of combinations of drugs is often necessary in palliative medicine, particularly in the terminal stage of life, when patients are no longer able to take medication orally. The use of infusers to administer continuous subcutaneous infusions is a well-established practice in the palliative care setting and enables several drugs to be given simultaneously, avoiding the need for repeated administrations and the effects of peaks and troughs in the doses of medication. The method is also appreciated by patients and caregivers in the home care setting because the devices and infusion sites are easy to manage. Despite their frequent use, however, the mixtures of drugs adopted in clinical practice are sometimes not supported by reliable data concerning their chemical and physical compatibility. The present study investigates the chemical compatibility of binary mixtures (morphine with ketorolac) and the physical compatibility of binary (morphine or methadone with ketorolac) or ternary mixtures (morphine with ketorolac and/or haloperidol, and/or dexamethasone, and/or metoclopramide, and/or hyoscine butylbromide) with a view to reducing the aleatory nature of the empirical use of such combinations, thereby increasing their safety and clinical appropriateness.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252547     DOI: 10.1007/s00520-011-1363-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  21 in total

Review 1.  The use of anti-inflammatory drugs in cancer pain.

Authors:  S Mercadante
Journal:  Cancer Treat Rev       Date:  2001-02       Impact factor: 12.111

2.  Opioid-sparing effect of diclofenac in cancer pain.

Authors:  S Mercadante; M Sapio; M Caligara; R Serretta; G Dardanoni; L Barresi
Journal:  J Pain Symptom Manage       Date:  1997-07       Impact factor: 3.612

3.  A small observational study of the longevity of syringe driver sites in palliative care.

Authors:  Sue Morgan; Nici Evans
Journal:  Int J Palliat Nurs       Date:  2004-08

4.  Comparison of the morphine-sparing effects of diclofenac sodium and ketorolac tromethamine after major orthopedic surgery.

Authors:  Ratan Alexander; Habib E El-Moalem; Tong J Gan
Journal:  J Clin Anesth       Date:  2002-05       Impact factor: 9.452

5.  A double-blind evaluation of the analgesic efficacy and toxicity of oral ketorolac and diclofenac in cancer pain. The TD/10 recordati Protocol Study Group.

Authors:  F Pannuti; G Robustelli della Cuna; V Ventaffrida; E Strocchi; C M Camaggi
Journal:  Tumori       Date:  1999 Mar-Apr       Impact factor: 2.098

6.  Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.

Authors:  Sofía Negro; María Luz Azuara; Yolanda Sánchez; Rodrigo Reyes; Emilia Barcia
Journal:  Support Care Cancer       Date:  2002-01       Impact factor: 3.603

7.  Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials.

Authors:  Emmanuel Marret; Okba Kurdi; Paul Zufferey; Francis Bonnet
Journal:  Anesthesiology       Date:  2005-06       Impact factor: 7.892

8.  The opioid-sparing effects of intravenous ketorolac as an adjuvant analgesic in cancer pain: application in bone metastases and the opioid bowel syndrome.

Authors:  S K Joishy; D Walsh
Journal:  J Pain Symptom Manage       Date:  1998-11       Impact factor: 3.612

9.  Compatibility and stability of ternary admixtures of morphine with haloperidol or midazolam and dexamethasone or methylprednisolone.

Authors:  A Vermeire; J P Remon
Journal:  Int J Pharm       Date:  1999-01-15       Impact factor: 5.875

10.  Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.

Authors:  Emilia Barcia; Rodrigo Reyes; María Luz Azuara; Yolanda Sánchez; Sofía Negro
Journal:  Support Care Cancer       Date:  2003-01-10       Impact factor: 3.603

View more
  3 in total

1.  Multidrug infusions in a Swiss palliative care unit: assessment of frequent combinations in terms of clinical effectiveness, compatibility, and stability.

Authors:  Tanja Fusi-Schmidhauser; Dario Caronzolo; Claudia Gamondi
Journal:  Support Care Cancer       Date:  2016-07-23       Impact factor: 3.603

2.  Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.

Authors:  María Espinosa-Bosch; Fuensanta Sanchez-Rojas; Catalina Bosch-Ojeda
Journal:  Eur J Hosp Pharm       Date:  2018-01-27

Review 3.  The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review.

Authors:  James Baker; Andrew Dickman; Stephen Mason; John Ellershaw
Journal:  PLoS One       Date:  2018-03-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.